Emmes, an international full-service Clinical Research Organization (CRO) committed to promoting public health and biopharmaceutical breakthroughs, recently revealed its acquisition of Essex Management. Essex delivers bioinformatics and health information technology (HIT) consulting services to governmental, private sector, and academic institutions.
Marking its sixth acquisition in just over two years, Emmes continues to pursue growth by incorporating both organic and complementary services for its clientele. Emmes CEO, Dr. Christine Dingivan, remarked that Essex’s bioinformatics proficiency, together with their CRO offerings, will broaden opportunities with various government agencies and enable inventive data tactics for biopharma clients. She emphasized Essex’s dedication to dismantling obstacles in clinical research through technology aligns seamlessly with Emmes’ mission and principles.
The fusion of the two organizations bolsters Emmes’ standing as a data-driven, comprehensive clinical research associate. Integrating Essex’s technical expertise with Emmes’ inventive data and advanced analytics solutions enhances their capacity to assist clients in tackling global health issues, both present and future. Both companies have an established history of collaboration with the National Cancer Institute (NCI).
Essex will contribute over 100 employees to Emmes’ existing 1,400-strong workforce, further elevating its status as a prominent biosciences employer. Kevin Hurley, CEO of Essex, expressed confidence in the new partnership, highlighting the potential for growth within NCI and other NIH agencies. He cited the revolutionary nature of data in clinical trials and the growing demand for data-driven research due to advancements in fields such as genomics.